This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

The Clinical Trials Industry’s Weekly News Update

physIQ rolls out data streaming tech scheme for CROs

Share this article

Medical insight services firm physIQ has launched a scheme it claims can provide CROs with access to patient data in real time.

According to the Chicago firm the scheme – called the Intrepid Partner Program - will provide clinical research organizations (CROs) that take part with a distinct advantage when competing for the business of life science companies.

The programs main benefit is that it gives CROs and sponsors more information in real time says John Wilson, senior vice president and general manager of life sciences for physIQ.

“Imagine moving from intermittently monitoring an immuno-oncology patient for a spike in temperature to detecting the onset of life-threatening inflammation many hours in advance of that temperature spike. This proactive approach fundamentally changes the gold standard on patient safety.”

Clinical trial innovation

Wilson framed the program as part of a wider shift that is seeing the trials sector embrace innovative technology.

“We are at an inflection point—AI will redefine patient safety standards, and physIQ is ready to bring these advances to the industry,” he said, adding that new technologies are changing how patient data is measured during studies.

“Imagine being able to measure a patient’s cardio-pulmonary health with a VO2Max test that requires no supervised exercise while achieving a 0.9 correlation to the gold standard Cardiopulmonary Exercise Test (CPET).

“This allows patients who are either physically incapable of exercise testing or geographically remote from CPET testing labs to be evaluated while carrying out normal activities of daily living in their home environment.”

CRO partners

The program launch comes a few months after physIQ teamed up with CRO Syneos Health to help run a Phase III study of an inhaled cardiovascular disease treatment candidate being developed by InCarda Therapeutics.

In addition to software, physIQ is providing its wearable sensors and FDA-cleared atrial fibrillation digital biomarker technology to patients taking part in the trial.


Share this article

Sign up for Clinical Insider email updates